L3VLUP
ProSign in

IQV · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IQVJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IQV
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterIQVJNJ
Q3 202021 holders, $4.8bn30 holders, $26.2bn
Q4 202022 holders, $5.2bn32 holders, $26.6bn
Q1 202118 holders, $5.4bn31 holders, $25.3bn
Q2 202126 holders, $6.1bn37 holders, $25.6bn
Q3 202124 holders, $5.9bn40 holders, $24.1bn
Q4 202124 holders, $6.9bn33 holders, $25.2bn
Q1 202221 holders, $5.2bn35 holders, $28.2bn
Q2 202215 holders, $3.9bn33 holders, $26.9bn
Q3 202221 holders, $3.1bn36 holders, $25.4bn
Q4 202219 holders, $3.9bn35 holders, $27.6bn
Q1 202324 holders, $4.4bn42 holders, $24.5bn
Q2 202323 holders, $5.5bn38 holders, $25.0bn
Q3 202322 holders, $5.4bn37 holders, $18.9bn
Q4 202314 holders, $6.2bn31 holders, $19.0bn
Q1 202415 holders, $6.9bn32 holders, $19.7bn
Q2 202420 holders, $5.8bn35 holders, $20.4bn
Q3 202423 holders, $6.3bn28 holders, $22.3bn
Q4 202422 holders, $5.7bn37 holders, $20.4bn
Q1 202522 holders, $5.1bn32 holders, $20.5bn
Q2 202521 holders, $5.4bn31 holders, $18.4bn
Q3 202517 holders, $5.9bn32 holders, $23.7bn
Q4 202518 holders, $7.0bn29 holders, $27.8bn
Q1 202611 holders, $4.7bn34 holders, $35.6bn
Q2 202619 holders, $5.3bn33 holders, $39.1bn
IQV

Iqvia HLDGS Inc

Holders
18
Reported value
$7.0bn
Buyers
19
Sellers
19

Breadth 0 among 92 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IQV (7)

Appaloosa LP, Artisan Partners LP, Balyasny Asset Management LLC, ExodusPoint Capital Management LP, Glenview Capital Management LLC, Harris Associates LP, Viking Global Investors LP

Only JNJ (18)

Acadian Asset Management LLC, Bridgewater Associates LP, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →